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Leishmania amazonensis parasites cause progressive disease in most inbred mouse strains and are associated with the development
of diﬀuse cutaneous leishmaniasis in humans. The poor activation of an eﬀective cellular response is correlated with the ability of
theseparasitestoinfectmononuclearphagocyticcellswithouttriggeringtheiractivationoractivelysuppressinginnateresponsesof
thesecells.Herewediscussthepossibleroleofphosphatidylserineexposurebytheseparasitesasamainregulatorofthemechanism
underlying subversion of the immune system at diﬀerent steps during the infection.
1.Leishmania Parasites
Leishmania parasites are heteroxenous kinetoplastid pro-
tozoan organisms, which undergo complete diﬀerentiation
upon a cycle of proliferation/diﬀerentiation in the midgut
of phlebotomine sand ﬂies followed by the transmission of
infectivemetacyclicpromastigotes[1,2]tomammalianhosts
during the insect blood meal. Once infecting mammalian
hosts, these organisms, from free-living protozoa, become
obligate intracellular parasites, residing and proliferating
inside phagolysosomes of mononuclear phagocytic cells as
amastigote forms.
In humans, Leishmania parasites can cause a broad spec-
trum of clinical manifestations from mild, self-resolving skin
diseases to potentially fatal, disseminated visceral diseases.
Theoutcomeoftheinfectionisdependentonmultiple,inter-
dependentfactors,suchasvectorspecies,parasitespeciesand
strain, genetic background, and immunological status of the
host. There are two main groups of parasites, stratiﬁed upon
the clinical outcome of the infection: the ones capable of
causing tegumentar and the ones capable of causing visceral
diseases. In both cases, disease is initiated by the bite of an
infected sand ﬂy, followed by the generation of a skin lesion,
mainly caused by the inﬂammatory response induced on
that site. In some cases the disease is conﬁned to the skin
or mucosal tissues, and is termed cutaneous (CL) or muco-
cutaneous (MCL) leishmaniasis, respectively. In addition,
diﬀuse cutaneous leishmaniasis (DCL) occurs when the
parasitedisseminatescausingtheappearanceofmultipleskin
lesions, in distal sites relative to the transmission site [3].
In a similar way, in visceral leishmaniasis, there is parasite
dissemination through blood and lymphatic vessels from
the initial lesion site. However, these parasites establish in
organsthatcompriseimportantpopulationsofmononuclear
phagocytes, such as bone marrow, spleen, and liver [4].
Among the clinical manifestations observed in humans
with the tegumentary disease, diﬀuse and mucocutaneous
leishmaniasis are the most severe forms. In both cases, most
patients were found in the South and Central America,
associated with L. amazonensis infection for DCL and L.
braziliensis infection for MCL.2 Journal of Parasitology Research
1.1. Diﬀuse Cutaneous Leishmaniasis. Diﬀuse cutaneous
leishmaniasis (DCL) is a rare clinical manifestation and
is characterized by the appearance of several nonulcerated
nodular skin lesions, uncontrolled parasite proliferation,
an ineﬃcient cellular immune response against parasite
antigens, and resistance to most therapeutic strategies [5, 6].
The lesions are characterized by a dense dermal inﬁltrate
of vacuolated macrophages heavily parasitized. The intense
parasitism in the DCL lesions reﬂects the functional state of
macrophages,whichareconsideredpermissive.Thedeﬁcient
macrophage activation in DCL hinders the elimination
of Leishmania resulting in a disorganized inﬂammatory
process, unable to control the infection. The determinants
of DCL are multifactorial and may be associated with both
immunologic and genetic events of the patient and the
pathogenic factors related to the parasite and vector. The
participation of factors associated with the parasite has
been shown by some authors although it is a point that
still remains to be further explored. In this context, the
exhibition of markers of apoptosis by the parasite could be
a contributing factor during host-parasite interactions as a
possible immunosuppressive mechanism of DCL [7].
2. ImmuneResponse
2.1. Classical L. major Infection. Experimental infection
models with Leishmania parasites have been extensively used
as a tool to study immune responses, especially regarding T-
cell diﬀerentiation [8, 9]. This is due to the fact that inbred
mice strains demonstrate speciﬁc patterns of susceptibility
and resistance to the disease [9, 10] which correlate with
the immune response built by these animals. The classical
experimental model that generated this knowledge was
infectionwithL.major parasites.C57BL/6miceinfectedwith
this parasite develop a Th1 CD4+ T-cell response, which is
highly eﬀective to activate leishmanicidal and inﬂammatory
mechanismsinmacrophages,leadingtointracellularparasite
destruction. In this case, a skin lesion is formed, which
regresses, becoming undetected around 6–8 postinfection
[9]. Nevertheless, latent parasites remain in the infected
tissue, providing antigens to maintain a protective immune
response that prevent reinfections [11]. On the other hand,
BALB/c mice infected with the same parasite species and
strain developed a Th2 CD4+ T-cell response, which is not
eﬃcient to promote macrophage classical activation, leading
to progressive disease. At the cellular level, this diﬀerence is
mainly due to the activation of a population of cells that
express a highly restricted T-cell receptor, Vβ4V α8, which
recognizes the LACK (Leishmania homologue of receptors
for activated kinase) antigen and rapidly produces IL-4,
necessary to deviate the immune response towards Th2 [12].
Currently,itisclearthattheproposed modelofsusceptibility
and resistance to Leishmania infection is quite reproducible
when working with some speciﬁc strains of L. major though,
for other strains and/or species, the picture is relatively more
complex. Indeed, eﬀective macrophage activation is the key
tocontroltheinfection;however,thephenotypedisplayedby
T cells in diﬀerent situations is not as polarized as observed
in the classical model. Actually, there are several papers that
suggest that most correlations between CD4+ T-cell response
anddiseasedevelopmentarenotstraightforward.BALB/cIL-
4 receptor knock-out (KO) mice remained susceptible to L.
major infection wheninfected with LV39 strain, which seems
to be due to an increased production of IL-10 by T cells
[13]. C57BL/6 mice infected with a L. major strain, isolated
from a patient with nonhealing lesions, still developed a
Th1 response but displayed a progressive disease [14]. In
addition, when infected with the IR173 strain of L. major,
CD4+ T cells from both BALB/c and the resistant mice
strain B10.D2 produce IL-4 very rapidly [15]. Other factors
such as infection route, number of parasites inoculated, and
type of infection (needle versus sand ﬂy inoculation) are
crucial to determine the type of response elicited (reviewed
in [9]). The complexity of the interactions that determines
the clinical and immunological outcome of the disease is
much less known, and apparently much more multifactorial
in other infection systems, such as the ones that involve L.
amazonensis infection.
2.2. L. amazonensis Infection: Beyond the Paradigm. Exper-
imental infection with L. amazonensis parasites leads to
progressive disease and uncontrolled lesion development
in all inbred mouse strains, including those ones that are
highly resistant to L. major infection. However, there is
a gradient of disease severity, ranging from BALB/c mice,
which develop a very fast lesion, that ulcerate, generating
extensive areas of necrotic tissue, to C3H.HeN mice that
still develop nonhealing lesions, however, displaying slow
progression rates [16, 17]. Nonetheless, the phenotype
displayed by diﬀerent mouse strains does not correlate with
dichotomic Th1/Th2 responses. Actually, in the analyzed
mouse strains such as BALB/c, C57BL/6, and C3H.HeN, it
was possible to observe CD4+ T cells capable of producing
diﬀerent types of cytokines such as Th2 cytokines (IL-4,
IL-5, and IL-13), Th1 cytokines (IFNγ,a n dT N F α), and
regulatory cytokines (TGFβ and IL-10), which characterizes
an unpolarized cellular response [18–20]. Targeted deletion
of the Il4 or Il10 gene [21, 22] causes minimal eﬀects
on lesion development and parasite tissue loads as well as
treatment of infected mice with IFNγ [23]o rI L - 1 2[ 22].
Interestingly, L. amazonensis promastigotes and, especially
amastigotes, are able to get through the innate immune
response almost unnoticeable. As mentioned before, the
main host cell for Leishmania proliferation in the mam-
malian host is the macrophage, which is, together with
dendriticcells(DCs),themainantigenpresentingcellsofthe
innate immune response. When compared to L. braziliensis
parasites, for example, L. amazonensis parasites are much
less capable of triggering the expression of CD40 and CD80
[24], both costimulatory molecules for T-cell activation,
and the production of IL-12p40 [24]. Actually, amastigote
infection is able to downregulate the expression of MHC
class II molecules [25], which, during macrophage infection,
is depending on sequestering these molecules inside the
parasitophorous vacuole for degradation [26, 27]. During
the ﬁrst week of infection in C57BL/6 mice, chemokines
such as CCL5, CCL3, CCL2, CCL4, and CCL11 as well
as their receptors, are not upregulated when compared toJournal of Parasitology Research 3
L. major infection, both at the lesion site and draining lymph
node [19]. Additionally, amastigote infection downregulates
several intracellular pathways that lead to DC activation such
as STAT 1, STAT 3 and Erk 1/2 phosphorylation and the
expression of the interferon-responsive elements IRF8 and
1, suggesting a global inhibition of inﬂammatory responses
of these cells [25]. The most well-characterized ligand for
amastigote recognition and internalization in macrophages
is the opsonizing antibodies produced throughout infection.
Triggering of Fc receptors on the host cells lead to IL-
10 production and has a pathogenic role [28]. These
events are necessary to evade the early immune response
culminating with the ineﬀective T-cell response observed in
most cases. In parallel to L. major infection in BALB/c mice,
where the oligoclonal Vβ4V α8C D 4 + T-cell population is
necessary to the development of susceptibility in the host
and is considered as pathogenic T cells, in L. amazonensis
infection, T cells, in a general way, seem to be highly
pathogenic. First of all, there is no clonal or oligoclonal T-
cell population involved, since there is no predominance
of a single or a group of Vβ c h a i n se x p r e s s e do nTc e l l s
that respond to L. amazonensis infection [29]. However, the
disruption of CD4+ Tc e l le ﬀector functions, as observed in
recombinase-activatinggeneKOmice(RAGKO),MHCclass
IItransactivatorKOmice(CIITAKO)andnudemiceleadsto
transient resistance to L. amazonensis infection, measured by
lesion development [30]. In addition, the adoptive transfer
of regulatory T cells also restrains pathogenic eﬀector T cells,
diminishing lesion size and parasite tissue loads [31]. The
mechanisms underlying pathogenic role of T cells for the
disease need to be determined.
3. Phosphatidylserine Exposure
3.1.HomeostasisandEﬀerocytosis. Phosphatidylserine(PS)is
a structural phospholipid present in virtually all membranes
and cell types. In normal cells these molecules face the
cytoplasmic leaﬂet of the plasma membrane, whereas during
apoptotic cell death these molecules translocate to the outer
surface. Once outside the cell, PS becomes one of the ligands
recognized by surrounding phagocytes to clear dying cells
[32]. However, PS in this model is not just one eat-me signal
[33]. PS is the most characterized tickling [34]l i g a n do f
apoptotic cells, which means that PS provides the signals
for the phagocyte to activate immunosuppressive and anti-
inﬂammatory mechanisms. PS recognition is mandatory to
prevent the establishment of a response to the self-antigens
engulfed by these cells during apoptotic cell clearance and to
avoid triggering inﬂammatory responses, especially during
the embryogenesis, when massive amounts of apoptotic
cells are generated and therefore, cleared [35–37], but
also in adults to prevent inﬂammatory immunopathologies
[32]. The intracellular events, receptors, and soluble factors
involved in this mechanism are still being deciphered and
are not the focus of this discussion. However, the eﬀects
of PS recognition in macrophages and DCs have a direct
impact in immune responses. Apoptotic cells actively induce
the production of the anti-inﬂammatory cytokines TGFβ,
PGE2, and PAF [35] and actively inhibit the production
of TNFα and IL-1β,e v e nu p o nL P Sc h a l l e n g e[ 35, 38].
Recognition of apoptotic cells also decreases the expression
of several activation markers and costimulatory molecules
by both human and murine DCs [39, 40] and regulates the
expression of cytokines involved with T-cell diﬀerentiation
at the transcriptional level [41, 42]. At the single cell level,
DCs that ingested an apoptotic cell and bacteria at the same
time are able to discern between them and only present
bacterial antigens. This is possible because the generation
of peptide-MHC class II complexes is controlled by toll-like
receptors (TLRs) in a strictly phagosome autonomous man-
ner. Since apoptotic cells do not trigger TLR activation, the
generationofstablecomplexesisinhibitedorabrogated[43].
All these eﬀects are fundamental to maintain homeostasis
and comprehend the last step of the eﬀerocytosis [44]o r
apoptotic cell clearance. However, it seems that intracellular
parasiteselegantlymakeuseofthesemechanismstoestablish
in the host [45–47]. Furthermore, some parasites mimic the
features of apoptotic cells to avoid host immune response, as
discussed in the next section.
3.2. Conserved Immune-Evasion Mechanism? One of the
most common PCD phenotypes is phosphatidylserine (PS)
exposure, which can be observed upon chemotherapy,
starvation, and heat shock conditions in several unicellu-
lar organisms [48–51] or is actively displayed in normal
conditions [52]. Our group observed that lesion-derived
amastigotes of L. amazonensis actively expose high levels of
PS, and by blocking this molecule there is a drastic decrease
in the ability of these parasites to infect and establish in the
macrophages [52]. These parasites are viable and capable of
diﬀerentiatingintopromastigoteformsinvitro(unpublished
data) and inside the sand ﬂy vector [53] and to infect
macrophages and mice [52, 54] and did not display other
markers of PCD. Therefore we denominated this mechanism
as apoptotic mimicry. PS exposure on amastigotes of L.
amazonensis occurs in virtually 100% of the parasites;
however, the amount of PS molecules depends on the
infected host. Parasites obtained from BALB/c mice expose
higher amounts of PS than the ones obtained from C57BL/6
mice[54].Thisobservationdemonstratesthattheamountof
PS at the surface of the amastigotes has a positive correlation
with the severity of the disease and suggests that the host is
able to modulate this phenotype of the parasite. Following
our description several other groups demonstrated the role
ofPSexposure andrecognition in diﬀerentinfection models.
Blood and cell-derived trypomastigotes of Trypanosoma
cruzi are able to expose PS, in contrast with epimastigotes,
which are not. In addition, infection with PS-exposing try-
pomastigote forms induces Smad nuclear translocation and
inducible nitric oxide synthase inhibition (iNOS), suggesting
an autocrine modulation of the host cell dependent on TGFβ
[55]. It is interesting to note that, among all T. cruzi parasite
stages, only the ones that are infective for mammalian cells
evolve the ability to expose PS, suggesting the presence of
an evolutionary link between PS exposure and the ability
to infect host cells. Similarly, Toxoplasma gondii peritoneal
tachyzoites expose PS at their surface, and the recognition
of this molecule seems to be necessary to downmodulate4 Journal of Parasitology Research
iNOS expression and activity upon macrophage infection
[56]. More recently, several papers have demonstrated the
role of exposed PS molecules for the infection by enveloped
viral particles. For human immunodeﬁciency Virus-1 (HIV-
1 ) ,P Sa tt h ev i r a le n v e l o p ei sac o f a c t o rf o rm o n o c y t e
infection [57]; in vaccinia virus infection, PS recognition
modulates the activity of proteins involved in cytoskeleton
reorganization such as p21-activated kinase (PAK) and the
small Rho GTPase Rac, leading to increased macropinocytic
activity and uptake of viral particles [58]. In addition, PS
exposure by tumor cell, microvesicles shed by transformed
cells, or endothelial cells in the intratumor environment
s e e m st ob ei n v o l v e di nd i ﬀerent events in tumor develop-
ment, maintenance, and metastasis [59, 60]. This knowledge
stimulated some researchers to evaluate the eﬃcacy of anti-
PSantibodies totreatviralandtumoraldiseases.Actuallythe
results so far are promising. In murine models of Lassa fever
(Pichinde virus) or murine cytomegaloviruses the treatment
eﬃcacy was very high, reaching complete cure (total absence
of detectable viral loads) in combination with available
antiaviral drugs [61]. For experimental tumoral disease, lung
cancer, pancreatic tumors, and glioblastomas were eﬃciently
treated, decreasing tumor growth and metastasis in some
casesorpotentiatingtheeﬀectofchemo-andradio-therapies
[62–64].
3.3. Leishmania amazonensis Infection: New Insights. Our
group has been committed to study the role of PS exposure
on the surface of diﬀerent isolates of L. amazonensis.W e
worked with the hypothesis that L. amazonensis isolates from
DCL patients would have higher PS exposure compared
withlocalizedcutaneousleishmaniasis(LCL),andthiswould
contribute to macrophage deactivation, favoring parasite
replication. For this, we compared PS exposure in L. ama-
zonensis isolates from DCL clinical cases in the active phase
of the disease, reported in Maranh˜ ao state in Brazil, to those
isolated from LCL patients of clinical cases from Bahia. The
results indicate that the isolates obtained from DCL patients
indeed displayed more PS than isolates from LCL patients
at early times postinfection. In addition, isolates from DCL
patients were more infective than the ones obtained from
LCL patients (Franc ¸a-Costa et al., unpublished results). On
the other hand, independent of parasite strain analyzed,
the parameters of infectivity correlated positively with the
exposure of PS in the parasites. These data suggest that
in human infections the pattern observed in mice when
comparing BALB/c versus C57BL/6 mice is maintained.
However, it is necessary to investigate the mechanisms by
which the recognition of PS on the surface of the isolates
of L. amazonensis deactivate the macrophage response.
Particularly,itwouldbenecessarytoevaluatewhetherfreshly
isolated parasites display this phenotype to validate our
analysis made on amastigotes derived from macrophages
infectedinvitrowithculturedpromastigoteparasitesisolated
from human lesions. We believe that understanding the
dynamics of PS expression, along with identiﬁcation of the
mechanisms involved in the immunosuppression of DCL
patients, can result in therapeutic targets for intervention in
the immunopathogenesis of this chronic and severe form of
leishmaniasis.
Inasimilarwayweareinterestedintheimmunomodula-
tory mechanisms underlying PS exposure in diﬀerent inbred
micestrains.Forthatwearecurrentlyevaluatingthesemech-
anisms during BALB/c infection, which induces high levels
of PS exposure on intracellular amastigotes. We observed
that PS exposure is intrinsic to the intracellular parasite and
cannot be observed in axenically cultured amastigotes but
upregulates very fast after internalization. However, these
levels are dramatically increased when infected macrophages
are in the presence of previously primed T cells or their
soluble products. We conﬁrmed these results by infecting
BALB/c nude mice where we observed that the amastigotes
obtainedfromthesemicedisplayminimallevelsofPS,which
a r ec o m p l e t e l yr e s t o r e di fw ea d o p t i v e l yt r a n s f e rp r i m e d
CD4+ T cells to nude mice (Wanderley et al. unpublished
results). Interestingly, these data indicate that one possible
roleforthepreviouslyreportedpathogenicTcells[31]would
be to induce PS exposure on intracellular amastigotes and,
therefore, contributing to the generation of highly infective
parasites. The T-cell-dependent PS exposure on amastigotes
seems to be dependent on the induction of iNOS expression
on host macrophages, and parasite survival is dependent
on the concomitant induction of arginase 1 expression
(Wanderley et al. unpublished results). We propose that
high levels of PS exposure are induced by parasite stress
delivered by iNOS activity. In this case, it is still unknown
whether PS exposure on amastigotes is indeed a phenotype
triggered by PCD or a speciﬁc process involving modula-
tion of PS translocation. Under PS-inducting conditions,
macrophages express high levels of arginase 1 (Wanderley
et al. unpublished results), that is the enzyme necessary
to produce ornithine, the precursor of polyamines. In this
situation, polyamines could protect the parasite from the
iNOS-dependent stress, stimulating parasite growth [66, 67]
and increasing DNA stabilization [68, 69]. We understand
that the unique characteristics of the T-cell response to
L. amazonensis infection contribute to the generation of a
perfect environment to stimulate and maintain increased
levels of PS on the surface of intracellular parasites. Prob-
ably the balance observed in infected BALB/c mice, when
disrupted, leads to the diﬀerences observed among diﬀerent
mouse strains. In Figure 1 we summarized our hypothesis
regarding the T-cell-dependent modulation of PS exposure
on intracellular amastigotes of L. amazonensis.
4. FinalRemarks
The observation of PS exposure as a strategy to evade
the immune system and persist in the mammalian host,
made initially in the experimental model of L. amazonensis
infection, was a breakthrough since it stimulated diﬀerent
groupsaroundtheworldtolookforthepossibilitiesforbasic
and applied research on the ﬁeld. Our group is still studying
the immunological, cellular, and molecular mechanisms
underlying control of PS exposure in parasites and the eﬀects
of its recognition by parasitized cells and organisms. We
believethatthiscouldbeamajorstrategyindiﬀerentsystemsJournal of Parasitology Research 5
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Figure 1: PS exposure on intracellular amastigotes of L. amazonensis: hypothesis for T-cell-dependent modulation. T cells primed by
leishmanial antigens display a pathogenic phenotype, characterized by the production of unpolarized cytokines [18, 31]. These cytokines
are able to activate both iNOS- and arginase 1-dependent intracellular macrophage pathways (Wanderley, JL et al. unpublished). In this
environment, amastigotes receive stress from iNOS-derived nitric oxide (NO) which triggers high levels of surface PS on the parasite
(Wanderley, JL et al. unpublished). Simultaneously, arginase 1 is also induced, and the outcome of this activation is an increase in polyamine
intracellular levels [65]. Polyamines are indispensable for parasite survival and proliferation, maintaining them even in the presence of NO
(Wanderley, JL et al. unpublished, [63]). Upon macrophage disruption, highly infective PSHIGH amastigotes are released, being capable of
infecting new host cells and of spreading the anti-inﬂammatory signals derived from PS recognition (dashed arrow). PV: parasitophorous
vacuole, ODC: ornithine decarboxylase, iNOS: inducible nitric oxide synthase, MΦ: macrophage, Am: amastigote.
where avoidance from immune surveillance is necessary to
establish a disease.
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